

## First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup

**Authors:** Keun-wook Lee,<sup>1\*</sup> Ken Kato,<sup>2</sup> Yuxian Bai,<sup>3</sup> Jianhua Shi,<sup>4</sup> Jufeng Wang,<sup>5</sup> Hongming Pan,<sup>6</sup> Sun Young Rha,<sup>7</sup> Ruixing Zhang,<sup>8</sup> Hidekazu Hirano,<sup>2</sup> Kensei Yamaguchi,<sup>9</sup> Zengqing Guo,<sup>10</sup> Yi Ba,<sup>11</sup> Lei Yang,<sup>12</sup> Hiroshi Tsukuda,<sup>13</sup> Yaling Xu,<sup>14</sup> Tao Sheng,<sup>15</sup> Silu Yang,<sup>14</sup> Liyun Li,<sup>14</sup> Do-Youn Oh,<sup>16</sup> Rui-hua Xu<sup>17</sup>  
\*Presenting author; †Corresponding author

**Affiliations:** <sup>1</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; <sup>2</sup>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; <sup>3</sup>Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China; <sup>4</sup>Department of Oncology, Linyi Cancer Hospital, Linyi, China; <sup>5</sup>Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China; <sup>6</sup>Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; <sup>7</sup>Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea; <sup>8</sup>Department of Gastroenterology and Hepatology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China; <sup>9</sup>Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, Tokyo, Japan; <sup>10</sup>Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China; <sup>11</sup>Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; <sup>12</sup>Department of Oncology, Nantong Cancer Hospital, Nantong, China; <sup>13</sup>Department of Medical Oncology, Izumi Municipal Hospital, Izumi, Japan; <sup>14</sup>Department of Clinical Development, BeiGene (Beijing) Co., Ltd, Beijing, China; <sup>15</sup>Department of Biostatistics, BeiGene, Ltd, Boston, MA, United States; <sup>16</sup>Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; <sup>17</sup>Department of Medical Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

### ABSTRACT

**Background:** Survival outcomes with platinum + fluoropyrimidine chemotherapy (chemo) alone as first-line (1L) therapy for advanced gastric/gastroesophageal junction cancer (GC/GEJC) are poor. Tislelizumab (TIS), an anti-PD-1 antibody, + chemo, showed significant overall survival (OS) benefit vs placebo (PBO) + chemo as 1L therapy in patients (pts) with advanced GC/GEJC in the randomized, double-blind, global phase 3 RATIONALE-305 study (NCT03777657). Here, we present results from the Asian pt subgroup analysis.

**Methods:** Eligible pts were randomized (1:1) to receive TIS 200 mg intravenously every 3 weeks plus investigator-chosen chemo (ICC [XELOX or FP]) or PBO + ICC until disease progression, or intolerable toxicity. Dual primary endpoints were OS in both the programmed death ligand-1 (PD-L1)+ (tumor area positivity ≥5%) and ITT analysis sets. Secondary endpoints included progression-free survival, objective response rate, duration of response, and safety.

**Results:** 748 pts (TIS + chemo: n=376, PBO + chemo: n=372, of N=997) enrolled from Asia (China, Korea, and Japan) were analyzed, including 403 pts in the PD-L1+ analysis set. In Korea, the study enrolled 131 patients across 10 sites. At final analysis, TIS + chemo showed improvements vs PBO + chemo in OS both in PD-L1+ (median [m] OS: 18.0 [95% confidence interval (CI): 15.0, 21.6] vs 14.0 mo [95% CI: 12.3, 15.5], hazard ratio [HR]=0.71 [95% CI: 0.56, 0.89]) and ITT analysis set (mOS: 16.4 [95% CI: 14.4, 18.0] vs 14.1 mo [95% CI: 12.8, 15.4], HR=0.83 [95% CI: 0.70, 0.97]). Incidences of grade ≥3 treatment-related adverse events (TRAEs) were 55.5% vs 50.0% and TRAEs leading to death

were 2.4% vs 0.8% for TIS vs PBO, respectively. TRAEs leading to discontinuation were reported in 17.1% pts in TIS + chemo arm vs 8.9% patients in PBO + chemo arm.

**Conclusions:** TIS + chemo produced a clinically meaningful improvement in OS vs PBO + chemo and a safety profile in pts with advanced GC/GEJC in the Asian subgroup that was consistent with published results in the overall study population.